TRS 006
Alternative Names: TRS-006Latest Information Update: 03 Mar 2022
Price :
$50 *
At a glance
- Originator Zhejiang Teruisi Pharmaceutical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Cancer
Most Recent Events
- 02 Mar 2022 Investigation ongoing in Cancer in China (Parenteral) (Zhejiang Teruisi Pharmaceutical pipeline, March 2022)